

The OncoAlert #ASCO21 Picks

Track: Metastatic Breast Cancer

(Dr.s Erika Hamilton, Matteo Lambertini, Maryam Lustberg, Stephanie Graff, Icro Meattini, Kenin Puney)

PALOMA3 Abstract #1000

Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3.

<https://bit.ly/3fGEhtW>

MONALEESA3 Abstract #1001

Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).

<https://bit.ly/3bNpVGQ>

Cabazitaxel Abstract #1008

Randomized multicenter trial of 3 weekly cabazitaxel versus weekly paclitaxel chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer (MBC).

<https://bit.ly/3bLqxNc>

H3B-6545 Abstract #1018

Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.

<https://bit.ly/3vfA72y>

Begonia Abstract #1023

BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).

<https://bit.ly/3wpHhBC>

Sysucc-002 Abstract #1003

Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial.

<https://bit.ly/3vdks3V>

DAWNA-1 Abstract #1002

Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study.

<https://bit.ly/3udiwHk>

Abstract #1005

Treatment-related side effects and views about dosage assessment to sustain quality of life: Results of an advocate-led survey of patients with metastatic breast cancer (MBC).

<https://bit.ly/3fenXRS>

VERONICA Abstract #1004

Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).

<https://bit.ly/2RFel4n>

Abstract #1013

Prospective longitudinal multi-omics study of palbociclib resistance in hormone receptor + /HER2- metastatic breast cancer.

<https://bit.ly/3vhV6SC>